Selank peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Shipping and taxes at checkout. Inventory is checked when adding to your bag.
Vectra publishes the laboratory certificate for every lot it releases. No released lot certificate is available for this size yet, so no current-lot results are shown.
Browse the COA libraryNo released COA is available for this lot.
Check document status| Analysis | Result | Status |
|---|---|---|
| Analytical results | Not available | No report |
Analytical results are not supplied until a certificate is released.
Check the printed lot on your vial against the certificate card that matches it.
Purity is not reported on this certificate
Selank peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for SelankRefer to the product label and lot-specific documentation for storage and handling instructions.
Selank supplied in the selected 40 mg Nasal Spray · 30 mL presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the certificate attached to this product and check that the lot matches your nasal spray. If a report is missing, contact Vectra with the product code and lot.
Selank is a heptapeptide, tuftsin-derived of 7 amino acids. Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Derived from tuftsin, an endogenous immunomodulatory tetrapeptide.
Reported to interact with the GABAergic system. We make no claim as to mechanism or effect.
Engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences, and clinically approved and used in Russia. No Western randomised controlled trial data is on record in our sources. First described by Institute of Molecular Genetics, Russian Academy of Sciences.
Studied in GABAergic signalling and anxiolytic models. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
As with Semax: approved clinical use in one jurisdiction, no Western trial record. Preclinical models report effects comparable to diazepam without sedation, dependence, or memory impairment — a preclinical comparison, not a clinical one.
Specific clinical adverse-event rates are not recorded in our sources.
Explore the published literature on Selank. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. See the lot-specific COA for product testing.
Your vial’s QR brings you to the product page, with its published COA alongside the product details.
These products are intended for laboratory research. Not for human or veterinary use.
Selank peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Shipping and taxes at checkout. Inventory is checked when adding to your bag.
Vectra publishes the laboratory certificate for every lot it releases. No released lot certificate is available for this size yet, so no current-lot results are shown.
Browse the COA libraryNo released COA is available for this lot.
Check document status| Analysis | Result | Status |
|---|---|---|
| Analytical results | Not available | No report |
Analytical results are not supplied until a certificate is released.
Check the printed lot on your vial against the certificate card that matches it.
Purity is not reported on this certificate
Selank peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for SelankRefer to the product label and lot-specific documentation for storage and handling instructions.
Selank supplied in the selected 40 mg Nasal Spray · 30 mL presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the certificate attached to this product and check that the lot matches your nasal spray. If a report is missing, contact Vectra with the product code and lot.
Selank is a heptapeptide, tuftsin-derived of 7 amino acids. Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Derived from tuftsin, an endogenous immunomodulatory tetrapeptide.
Reported to interact with the GABAergic system. We make no claim as to mechanism or effect.
Engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences, and clinically approved and used in Russia. No Western randomised controlled trial data is on record in our sources. First described by Institute of Molecular Genetics, Russian Academy of Sciences.
Studied in GABAergic signalling and anxiolytic models. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
As with Semax: approved clinical use in one jurisdiction, no Western trial record. Preclinical models report effects comparable to diazepam without sedation, dependence, or memory impairment — a preclinical comparison, not a clinical one.
Specific clinical adverse-event rates are not recorded in our sources.
Explore the published literature on Selank. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. See the lot-specific COA for product testing.
Your vial’s QR brings you to the product page, with its published COA alongside the product details.
These products are intended for laboratory research. Not for human or veterinary use.
Our sources carry no CAS number, molecular formula, molecular weight, or storage data for Selank.
Not approved as a medicinal product in the United States. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Our sources carry no CAS number, molecular formula, molecular weight, or storage data for Selank.
Not approved as a medicinal product in the United States. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
